RT @doctorRBC: BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%)
Tweet Content
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA.
Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16).
~60% PASI100 in BKZ
#ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
Show on Archive Page
On
Display in Search Results
On
PDQ
Off